Idexx Laboratories

IDXX

Market cap $46.4B

IDEXX Laboratories, Inc. IDXX is expanding its global commercial capabilities to support continued growth in its CAG Diagnostics recurring revenue stream. The company's software ecosystem remains a key pillar of its value proposition.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

IDXX stock surges over the past year, fueled by strong diagnostics growth, innovation traction and expanding global demand in pet healthcare markets.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 first quarter financial results for Tuesday, May 5, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2026 Earnings Snapshot through a link on the IDEXX website,.

Idexx (IDXX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Cancer Dx Panel with canine lymphoma detection helps clinicians investigate sooner and plan next steps with confidence.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

IDXX shares jump 39% in a year, as CAG Diagnostics' recurring revenues, diagnostic innovations and software growth fuel momentum.